Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
Rchr
J-GLOBAL ID：201001056555169072
Update date: Sep. 19, 2024 Ishiyama Ken
イシヤマ ケン | Ishiyama Ken
Clips- 2020 - 2023 トロンボポエチン受容体作動薬ロミプロスチムの造血への影響とDNA修復効果の検証
- 2017 - 2020 Analysis of mechanisms underlying preferential commitment of hematopoietic stem cells with del(13q) in patients with autoimmune hematopoietic failure
- 2016 - 2018 Development of diagnostic kit for myelodysplastic anemia
- 2009 - 2011 Identification of auto-antigens which trigger the development of immune-mediated bone marrow failure
- 2003 - 2004 Analysis of autoantigens in aplastic anemia : identification of an epitope recognized by CD4^+ T cells specific to hematopoietic progenitor cells
- Shuhei Kurosawa, Yoshimitsu Shimomura, Ken Ishiyama, Kyoko Fuse, Yutaka Shimazu, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Satoshi Takahashi, Masatoshi Sakurai, et al. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study. Bone marrow transplantation. 2024
- Shuhei Kurosawa, Yoshimitsu Shimomura, Hidehiro Itonaga, Yuta Katayama, Makoto Onizuka, Masatsugu Tanaka, Hikaru Kobayashi, Yukiyasu Ozawa, Masashi Sawa, Junya Kanda, et al. Comparison of melphalan dose in patients with myelodysplastic syndrome undergoing allogeneic transplantation with reduced-intensity conditioning. Transplantation and cellular therapy. 2024
- Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, et al. Outcomes of Transplant-eligible Patients with Myelodysplastic Syndrome with Excess Blasts Registered in an Observational Study: The JALSG-CS11-MDS-SCT. Annals of Hematology. 2024. 103. 1. 307-320
- Takaaki Konuma, Satoshi Yamasaki, Ken Ishiyama, Shohei Mizuno, Hiromi Hayashi, Naoyuki Uchida, Masashi Shimabukuro, Masatsugu Tanaka, Takuro Kuriyama, Makoto Onizuka, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free survival compared with matched sibling donors during non-remission status: MSD vs alternative donors transplant for patients over 50 years of age with AML. Transplantation and cellular therapy. 2023
- Yoshitaka Zaimoku, Takamasa Katagiri, Noriharu Nakagawa, Tatsuya Imi, Hiroyuki Maruyama, Hiroyuki Takamatsu, Ken Ishiyama, Hirohito Yamazaki, Toshihiro Miyamoto, Shinji Nakao. HLA Class I Allele Loss and Bone Marrow Transplantation Outcomes in Immune Aplastic Anemia. Transplantation and cellular therapy. 2023
- 島津 浩, 那須 涼, 赤川 由里, 栂野 富輝, 石山 謙, 半下石 明. 当院における中高齢者の骨髄系腫瘍に対する同種造血幹細胞移植の成績について. 日本血液学会学術集会. 2023. 85回. 110-110
- 石山 謙, 臼杵 憲祐, 池添 隆之, 後藤 明彦, Myren Karl-Johan, Tomazos Ioannis, 下野 明彦, 二宮 治彦, 櫻井 政寿, 中尾 眞二, et al. 日本人発作性夜間ヘモグロビン尿症患者におけるravulizumabおよびeculizumabの選択. 臨床血液. 2023. 64. 1. 9-17
- 小西達矢, 松田健佑, 糸永英弘, 土岐典子, 小澤幸泰, 松岡賢市, 池田宇次, 神田善伸, 福田隆浩, 諫田淳也, et al. Impact of Early CMV Reactivation on Relapse in Adult Patients with MDS after Allogeneic HSCT. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 45th
- 村宏樹, 川島隼人, 吉野裕貴, 萩原剛志, 井美達也, 松浦絵里香, 材木義隆, 細川晃平, 丸山裕之, 吉田晶代, et al. Two Cases of Lung Cancer That Rapidly Progressed after Allogenic Stem Cell Transplantation. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 45th
- 酒井志保, 古一素江, 石山謙, 徳丸季聡, 岡本浩一, 宮本敏浩, 森山秀樹. Oral-derived Nutritional Intake from Allogeneic HSCT to Discharge from the Hospital. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 45th
-
当院における中高齢者の骨髄系腫瘍に対する同種造血幹細胞移植の成績について
(日本血液学会学術集会 2023) -
シクロスポリン+ロミプロスチム療法中に血球減少が増悪し,骨髄穿刺・生検所見で乖離を認めたCsA依存性再生不良性貧血の1例
(臨床血液 2023) -
HLA遺伝子型が再生不良性貧血の同種造血細胞移植成績に及ぼす影響 TRUMPデータ解析
(日本血液学会学術集会 2023) -
骨髄異形成症候群に対するHLA半合致末梢血幹細胞移植とHLA適合非血縁者間移植の比較
(日本血液学会学術集会 2023) -
発作性夜間ヘモグロビン尿症患者におけるラブリズマブ高濃度製剤の安全性、有効性に関する検討
(日本血液学会学術集会 2023)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
